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Abstract
As average life expectancy rises throughout the world, neurodegenerative diseases have emerged 
as one of the greatest global public heath challenges in modern times. Substantial efforts have 
been made in researching neurodegenerative diseases over the last few decades, yet their 
predominantly sporadic nature has made uncovering their etiologies challenging. Mounting 
evidence has suggested that factors like damage-associated molecular patterns (DAMPs) released 
by stressed and dying neurons are likely involved in disease pathology and in stimulating chronic 
activation of microglia that contributes to neuronal oxidative stress and degeneration. This review 
focuses on how the microglial integrin receptor Mac1 and its downstream effector NADPH 
oxidase (NOX2) contribute to maintaining chronic neuroinflammation and are crucial in 
inflammation-driven neurotoxicity in neurodegenerative diseases. Our hope is to provide new 
insights on novel targets and therapies that could slow or even halt neurodegeneration.
Introduction
Neurodegenerative diseases are characterized by a progressive, yet selective regional 
neuronal loss, whereby chronic neuroinflammation has been verified to contribute to the 
degenerative process [1–4]. Microglia are widely considered the predominant resident 
effector cells of the immune system in the central nervous system (CNS) and become 
activated in response to stimuli such as chemicals and toxins detected in their 
microenvironment. Microglia typically are activated until they, and other infiltrating 
leukocytes that may have been recruited, have sufficiently cleared the insult or source of 
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deleterious stimuli. Yet in condition where the deleterious stimuli persist, this results in 
unresolved neuroinflammation that can damage proximal neurons. Collateral damage to 
neurons releases endogenous proteins and cell membrane fragments that can re-stimulate the 
activation of microglia forming a chronic state of activation known as reactive microgliosis. 
Evidence suggests that this low-grade chronic neuroinflammation contributes to progressive 
neurodegeneration in diseases such as Parkinson’s and Alzheimer’s diseases. Though the 
receptors that detect microbial pathogens are shared among all innate immune cells 
including microglia, these cells are also attuned to detect endogenous cellular components 
released by cells during stress, injury and death through the same receptors [5]. Though the 
structure of these intrinsic and extrinsic stimuli are highly variable, they are thought to 
activate microglia through receptor-mediated signaling of pattern recognition receptors such 
as Toll-like receptors (TLRs), Nod-like receptors (NLRs), and RIG-1 like receptors (RLRs) 
or through scavenger, integrin, or RAGE receptors that have similarly promiscuous binding 
capabilities [1,6–11].
Traditionally, neuroinflammation was also described through the immunological activation 
of astrocytes, yet today the functional role of astrocytes during neuroinflammation is less 
clear. The expression of the above-mentioned receptors by astrocytes has been inconclusive 
and many of their immune functions are still controversial since they were historically 
confirmed in vitro using isolation methods that sill resulted in significant microglial 
contamination that could alter the outcome of the studies. A recent study from our group 
demonstrated that, contrary to much of the reported literature, astrocytes may not possess the 
ability to directly recognize innate immune stimuli such as the bacterial endotoxin LPS. In 
fact, they rather depend on crosstalk with activated microglia to elicit their activation and 
promote the release of neurotrophic factors as a counterbalance that supports neuronal 
survival from the collateral damage generated by activated microglia during 
neuroinflammation [12]. For this reason, we have chosen to focus on microglia with this 
review. Furthermore, even though circulating monocytes are known infiltrate the CNS and 
differentiate into microglial-like macrophages during neuroinflammation [13,14], we will 
also not be addressing the role of these infiltrating leukocytes since they are only thought to 
play a pivotal role in disease with high-grade neuroinflammation such as traumatic brain 
injury and multiple sclerosis and are not thought to be as important in conditions of low-
grade neuroinflammation.
Neuroinflammation is a self-defense reaction to combat pathogen infection or clear and 
restore injuries in the CNS; this reaction is initially carried out by microglia and shaped by 
reactive astrocytes and other infiltrating leukocytes. Neuroinflammatory responses are 
typically transient and help restore CNS homeostasis, however in pathological conditions 
neuroinflammation may continue unresolved becoming persistent [15]. Yet the mechanism 
by which acute neuroinflammation turns to chronic in neurodegenerative diseases remains 
largely unknown. Here we have reviewed the literature on reactive microgliosis and 
hypothesize that persistent Mac1 signaling on microglia is required for continuous activation 
of NADPH oxidase (NOX2), the main catalytic enzyme responsible for generating 
extracellular superoxide required to maintain self-propelling reactive microgliosis found in 
chronic neuroinflammation.
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Role of Toll-like receptors in the pathogenesis of acute and chronic 
neuroinflammation
Acute inflammation
Acute neuroinflammation is typically initiated by detecting the pathogen-associated 
molecular patterns (PAMPs) from microorganisms, or the damage-associated molecular 
patterns (DAMPs) molecules released from injured or dying neurons. At this stage, 
microglia are recruited to clear these signals by preventing infection or restoring injuries in 
the brain [16]. Toll-like receptors are the most extensively studied receptors stimulated by 
both PAMPs and DAMPs and are readily expressed on microglia [17]. TLRs signal through 
various adaptor molecules to stimulate the activation of nuclear factor-κB (NF-κB) and the 
mitogen-activated protein kinases (MAPKs) like extracellular signal-regulated kinase ½ 
(Erk1/2), p38, and JNK to induce the production of proinflammatory cytokines and 
chemokines [18]. DAMPs associated with the pathology of several neurodegenerative 
diseases act on TLRs [19] such as α-synuclein that acts on TLR2 [20] and both β-amyloid 
[21–23] and HMGB-1 that act on TLR2, TLR4 and TLR9 [24,25]. Furthermore, brains from 
patients with neurodegenerative diseases or that have undergone normal aging had far 
greater TLR gene expression and expression of pro-inflammatory genes associated with 
TLRs signal transduction [26,27] likely due to increased DAMPs during neurodegeneration. 
These results put forward the hypothesis that an aberrant TLR activation may contribute to 
the process of aging and neurodegenerative diseases.
Chronic inflammation
It is widely accepted that chronic low-grade neuroinflammation plays a key role in the 
pathogenesis of neurodegeneration. However, the molecular mechanism mediating chronic 
neuroinflammation is less clear. To avoid the excessive damage of host cells by harmful and 
inappropriate inflammatory responses during the acute phase of inflammation, TLR signals 
are often promptly dampened or terminated through multiple mechanisms, such as 
dissociation of adaptor complexes, degradation of signaling proteins, and transcriptional 
regulation (also known TLR tolerance) [28]. Although TLRs have been widely implicated in 
neuroinflammation, their role in maintaining reactive microgliosis and chronic 
neuroinflammaiton has not been well studied. For this reason, we suspect that although 
TLRs are crucial in the initiation of immune responses during the early phases of 
neurodegenerative diseases, the maintenance of chronic neuroinflammation is likely 
mediated by another receptor that detects neuronal DAMPs.
Microglial Mac1 is essential in maintaining chronic neuroinflammation
Our group and others have demonstrated in rodents that the integrin receptor Mac1 (also 
known as CD11b/CD18, complement receptor 3 [CR3], or αMβ2) is essential in maintaining 
chronic reactive microgliosis and in driving inflammation-mediated neurodegeneration [29–
31]. Historically, Mac1 has been recognized as an adhesion molecule that participates in cell 
signaling during cell-to-cell contact. Yet, during inflammation, Mac1 is required for 
chemotaxis and phagocytosis in activated neutrophils and macrophages [32,33]. 
Additionally, the expression of Mac1 is elevated in brains from patients with Alzheimer’s 
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disease [34] and in MPTP animal models of Parkinson’s disease [35]. Most importantly, 
microglial Mac1 is capable of binding neuronal DAMPs including α-synuclein [36], β-
amyloid [8], HMGB-1 [9], and myelin [37] that are typically associated with 
neurodegeneration to induce signaling and their subsequent activation. Furthermore, in vivo 
and in vitro studies have shown that the genetic ablation of Mac1 results in decreased 
neurodegeneration when stimulated with the neurotoxicant MPTP [31] or the administration 
of the exogenous DAMP peptides α-synuclein [36] and β-amyloid [8]. Based on these 
findings we suspect Mac1 on microglia is the DAMP receptor responsible for maintaining 
the self-perpetuating reactive microgliosis required in chronic neuroinflammation (Figure 1; 
[9]).
Mac1–NOX2 signaling bridges chronic neuroinflammation and progressive 
neurodegeneration
Recent studies have indicated microglial NOX2 activation as an important downstream 
effector of Mac1 signaling [9,29,38]. NOX2 is composed of cytosolic subunits (p47phox, 
p67phox, p40phox, and the small Rho GTPase, Rac1 or Rac2) and membrane-bound subunits 
p22phox and gp91phox [39]. Upon stimulation, cytosolic subunits of NOX2 translocate and 
bind to the membrane subunits to assemble the catalytically active form of NOX2 that 
produces extracellular superoxide [40]. When HMGB-1 binds to Mac1 it induces the 
expressions of several proinflammatory factors including TNF-α, IL-1β and NO through the 
activation of NF-κB signal pathway and the production of superoxide through the activation 
of NOX2 [9]. Further interrogation into the mechanism that links DAMPs binding to 
Mac1to NOX2 activation using β-amyloid shows that the conformational changes of Mac1 
upon binding increases the level of PI3K, phosphorylating p47phox and PIP3 to trigger their 
translocation from the cytosol to membrane-bound NOX2 to generate superoxide production 
[8]. Interestingly, when examining the chemotactic role of Mac1 towards aggregated α-
synuclein, NOX2 activation was required to produce superoxide that rapidly transmutes into 
H2O2 that activates tyrosine protein kinase Lyn to phosphorylate the F-actin–associated 
protein cortactin—mediating actin rearrangement required for directional microglia 
migration [36].
During chronic neuroinflammation, microglia maintain chronic low-grade 
neuroinflammation through continuous transcription of mRNA of pro-inflammatory factors 
such as TNF-α, IL-1β, COX2 as well as NOX2 [41]. The importance of NOX2-generated 
superoxide in the progression of inflammation-driven degeneration in both in vitro and in 
vivo models has been established by using microglia derived from NOX2 knockout mice and 
using NOX2 inhibitors diphenyleneiodonium (DPI) or apocynin [42–44]. Interestingly, the 
genetic ablation of CD11b, the alpha subunit of the Mac1 receptor in mice, showed a similar 
ability to prevent superoxide release and attenuated neurodegeneration during 
neuroinflammation [31,38]. This attenuation occurs by preventing reactive microgliosis 
along the Mac1-NOX2 axis, whereby microglial Mac1 re-stimulated microglial activation in 
response to neuronal-derived DAMPs to induce receptor-mediated signal transduction that 
activates NOX2 to generate superoxide [31]. This pathway, beyond that of TLRs, is crucial 
for maintaining chronic neuroinflammation and driving inflammation-mediated oxidative 
stress that leads to neurodegeneration.
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Neuronal NOX2 increases neuronal oxidative stress in aging and inflammatory conditions
How microglia-produced proinflammatory factors cause neuronal damage or death is a 
critical question in neurodegeneration that has not been clarified yet. Evidence suggests that 
ROS produced from the Mac1-NOX2 signaling pathway plays a crucial role in 
neuroinflammation-mediated oxidative stress in neurons that results in their degeneration 
[40]. Neurons are highly sensitive to oxidative stress. During inflammatory conditions, 
continuous bombardment of pro-inflammatory factors released from microglia gradually 
increase intracellular ROS (i.e. hydrogen peroxide and peroxynitrite produced by a reaction 
between superoxide and nitric oxide) within neighboring neurons. ROS-related oxidative 
stress impairs neuronal mitochondrial functions by the reduction of membrane potential, 
inhibition of ATP production, and greater production of mitochondria-derived ROS [41,45]. 
Moreover, upregulation of neuronal NOX expression results from the increased level of 
ROS and further enhances the production of ROS inside neurons. This feed forward chain 
reaction likely drives another vicious cycle within neurons generating even more ROS as 
mitochondria begin to fail until ROS over-production and oxidative stress begin to form 
protein aggregates, lysosomal malfunction and impaired clearance of dysfunctional 
mitochondria overall driving neuron death (Figure 2) [40].
Novel anti-inflammatory therapeutic strategies for neurodegenerative diseases by 
targeting NOX2
Oxidative stress and neuroinflammation are among the most common features shared in all 
neurodegenerative diseases. Antioxidant therapy has been considered as a strategy to treat 
neurodegenerative diseases, however the administration of antioxidants (e.g., vitamin C, 
vitamin E and co-enzyme Q10) showed marginal symptomatic improvements and was 
unable to halt disease progression in clinical trials for Alzheimer’s and Parkinson’s disease 
[46–49]. Since anti-oxidants are designed to neutralize unpaired electrons of free radicals, 
they are ineffective against hydrogen peroxide and peroxynitrite, the two species thought to 
be most effective at driving oxidative stress in neurons. Furthermore, targeting inflammation 
as a method of neutralizing inflammation-mediated oxidative stress in neurodegenerative 
diseases has also been investigated using nonsteroidal anti-inflammatory drugs (NSAIDs) in 
clinical trials with similar ineffective results. This is partly because anti-inflammatory 
therapies target the production of specific cytokines or prostaglandins rather than the 
mechanism underlying chronic neuroinflammation generation (i.e., the Mac1-NOX2 axis). 
For this reason, therapies that disrupt the Mac1-NOX2 axis could be more effective 
strategies in extinguishing chronic neuroinflammation, limiting the neuronal oxidative stress 
that contributes to neurodegeneration. There are two known anti-inflammatory compounds 
that reduce Mac1 expression, the natural flavonoid baicalin derived from the roots and 
leaves of the Scutellaria baicalensis plant [50] and the pharmaceutically synthesized 
leumedin NPC 15669 [51]. Unfortunately, NPC 15669 failed during Phase I clinical trials 
for undisclosed safety reasons. Interestingly, our group has shown that inhibition of NOX2 
in the Mac1-NOX2 axis provides great efficacy at preventing inflammation-driven 
neurodegeneration in pre-clinical studies of Parkinson’s disease. Our laboratory has 
identified several compounds including morphinans (e.g. dextromethorphan, sinomenine, 
naloxone and naltrexone) [52–55], peptides (e.g. dynorphine and Gly-Gly-Phe) [56,57], and 
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adrenergic receptor agonist (e.g. salmeterol) [58] that inhibit NOX2-generated superoxide to 
limit inflammation-driven oxidative stress and neurodegeneration (Fig. 3). Among the most 
recently published compounds, the established NOX inhibitor diphenyleneiodonium (DPI) 
was precluded from use in humans due to its high toxicity at micromolar concentrations. 
Interestingly, when DPI was administered in vivo at subpicomolar concentrations it not only 
had high specificity with long-term NOX2 inhibition but also resulted in no detectable acute 
cytotoxicity [42]. DPI was so effective, as it was shown to protect mice in multiple models 
of Parkinson’s disease even when administered post disease onset [42]. Though DPI had 
such great initial preclinical success, we are currently screening several novel blood-brain-
barrier permeable NOX2 inhibitors with even greater efficacy and specificity that might 
become promising clinical therapeutics to extinguish chronic neuroinflammation in 
neurodegenerative diseases by targeting the Mac1-NOX2 axis.
Conclusions
The role of low-grade, chronic neuroinflammation in the pathogenesis of neurodegenerative 
diseases continues to be strengthened. Yet our lack of understanding of the cellular and 
molecular mechanisms that shift inflammation from a tightly controlled acute event into a 
self-propelling cycle that causes collateral damage has prevented us from developing better 
targeted interventions to prevent chronic neuroinflammation. The most recent hypothesis 
based on data collected from healthy and diseased human brain tissue and animal models 
suggests that gradual increased release of neuronal DAMPs likely drive and maintain 
reactive microgliosis in neurodegenerative diseases. Although studies have shown that TLRs 
could be the central receptors for DAMPs during the progression of neurodegenerative 
disease, we present data that supports the Mac1-NOX2 signaling pathway is not only 
stimulated by DAMPs but also necessary for neuroinflammation to become sustained and 
pathological. Unlike TLRs, Mac1 can undergo multiple activations without tolerance-like 
modulations which more closely resemble the pattern of chronic neuroinflammation seen in 
neurodegenerative diseases. Thus, we believe designing therapies that disrupt the Mac1-
NOX2 axis will likely show great promise in breaking the vicious cycle of uncontrolled 
neuroinflammation that drives oxidative stress and neurodegeneration in neurodegenerative 
diseases.
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Figure 1. 
Reactive microgliosis drives chronic and progressive neurotoxicity. Microglia can initiate 
neurotoxicity by recognizing pro-inflammatory stimuli, such as cytokines, pathogen 
associated molecular patterns (PAMPs) from microbial pathogens to become activated and 
producing cytotoxic factors to damage neurons. Damage-associated molecular patterns 
(DAMPs) released from damaged/dead neurons can sustain microglia activation (reactive 
microgliosis), which cause further neuronal damage/death. Microglia Mac1 could recognize 
DAMPs and activate downstream NADPH oxidase (NOX2) to produce superoxide anions 
and its associated reactive oxygen species (ROS), such as hydrogen peroxide, which play a 
critical role in reactive microgliosis and driving the chronic neurodegeneration.
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Figure 2. 
Inflammation-derived oxidative stress leads to a vicious cycle inside the damaged neurons 
and causes neuronal death. Sustained release of neurotoxic factors from activated microglia 
continually bombards neurons and increases neuronal oxidative stress during chronic 
neuroinflammation. The oxidative stress causes mitochondria dysfunction, which could 
upregulate the expression of neuronal NOX, produce more ROS and lead to progressive 
neurodegeneration.
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Figure 3. 
The novel promising anti-inflammatory therapies. The conventional therapies target a 
limited number of pro-inflammatory factors and failed to block disease progression. The 
novel anti-inflammatory therapy targets upstream neuro-inflammatory signaling by 
inhibiting microglial NOX2, which in turn reduces superoxide production and over-
activation of microglia and thereby reducing the release of most pro-inflammatory and 
detrimental factors.
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